Delivery Order HT942524D0009-HT942524F0289
Award Date
9/6/24
Potential Completion Date
9/13/24
Potential Value
$34K
Federal Agency
Defense Health Agency
Awardee
Leinco Technologies, Inc.
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Fenton, MO, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order (HT942525F0013) awarded to Leinco Technologies, Inc., a self-certified small disadvantaged business and manufacturer of goods, by the Defense Health Agency (DHA) on October 31, 2024. The $33,125.00 firm fixed-price contract is for the provision of monoclonal antibodies derived from in-vivo genetically immunized knockout mice expressing the interferon-alpha/beta receptor alpha chain protein. This contract supports the agency's research and development efforts related to...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $27,474,922.00, was awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., for "Research, Development, Production and Support for Clinical Trials - Broadly Neutralizing Monoclonal Antibodies (BNMABs)." The contract does not have a set-aside...
The federal contract award HHSN272201500446P was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and research products. The $3,900.00 firm-fixed-price purchase order is for the supply of LEAF Purified Anti-Mouse CD172a (SIRPa) antibodies to support research efforts. This award does not have a set-aside designation. Biolegend, as a...
This federal contract award, valued at $3,706,224, is a delivery order issued under prime contract 75N91019D00024 to Leidos Biomedical Research Inc. by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The delivery order is for COVID-19 related operational efforts. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. that provides a broad range of research, development, and production services to federal...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Miltenyi Biotec, Inc., a global biotechnology company. The $6,671 firm-fixed-price purchase order is for the supply of ANTIBODIES. Miltenyi Biotec is an experienced federal contractor, having received numerous awards from agencies such as the NIH, Department of Veterans Affairs, Food and Drug Administration, Department of Defense,...
This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....
<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $12.2 million delivery order contract to Leidos Biomedical Research Inc. to support research, development, and production efforts related to Ebola bispecific antibody development. As the prime contractor, Leidos Biomedical Research will perform work at its place of performance in Fort Detrick, Maryland under a cost plus fixed fee contract running from September 2022 through July 2028.</p>
Leidos Biomedical Research Inc. was awarded a $19,358,814 delivery order contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to support human immunodeficiency virus (HIV) monoclonal antibody development. Specifically, the prime contractor will support cell line development, process development, analytical development, reagent production, manufacturing, and testing under the objectives of the prime award. The period of performance for these...
This firm-fixed-price federal purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical products. The $31,957.50 contract supports the supply of various antibodies, reagents, and kits to advance research initiatives across NIAID, with no set-aside designation. Biolegend has a long history of providing specialized products for...
This is a $18,328.50 firm-fixed-price purchase order contract awarded to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies, by the National Institutes of Health (NIH) Clinical Center. The contract is for the provision of reagents and kits to support various research efforts across disease areas including COVID-19, multiple sclerosis, infectious diseases, allergies, immunology, oncology, and bone marrow disorders. Biolegend has a history of federal awards with the...